Long-term survivors of metastatic lung cancer: health, quality of life, and needs

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational follow-up of adults in France who have lived three or more years after a diagnosis of metastatic NSCLC or SCLC and are not receiving cytotoxic chemotherapy. Participants complete standardized questionnaires (HAD, QLQ-LC13, AMU) at inclusion, at 6 and 12 months, and then annually up to five years while clinical data are collected during routine visits. The study will record treatment history, new medical conditions (including cardiovascular disease, diabetes, and second cancers), socioeconomic impacts, and return-to-work outcomes. Data are collected at participating French centers to characterize long-term responder needs and inform survivorship care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years old
* Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance).
* Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance

Exclusion Criteria:

* Difficulties for understanding French
* Patients undergoing treatment with cytotoxic chemotherapy
* Patients under legal guardianship, under curatorship or tutorship
* Insufficient cognitive capacity to answer questions
* Inability to obtain data collection (lost to follow-up, patient's refusal for data collection)
* Patients refusing the collection of their data (an information sheet will be provided)

Where it's running

• CH du Pays d Aix
  Aix-en-Provence, France Recruiting
• Hôpital Henri Duffaut
  Avignon, France Recruiting
• APHP Hôpital Avicennes
  Bobigny, France Recruiting
• CHU Morvan
  Brest, France Recruiting
• Centre Hospitalier du Cotentin
  Cherbourg, France Recruiting
• CHU Hôpital Montpied
  Clermont-Ferrand, France Recruiting

Study contacts

• Principal investigator: Lionel FALCHERO — Gfpc
• Study coordinator: Alice MOGENET
• Email: Alice.MOGENET@ap-hm.fr
• Phone: +33 (0)4 73 98 39 86

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC

  In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07630168

• Combination immunotherapy and radiotherapy in metastatic non-small cell lung cancer

  This trial will test whether adding immunotherapy to radiotherapy helps people with metastatic non-small cell lung cancer who have progressed on prior immunotherapy.

  Recruiting Phase 2 University of Chicago · Chicago, Illinois · NCT07603856

• Thinking and mood changes from ALK/ROS1 targeted drugs in metastatic lung cancer and a patient-research care pathway

  This project will look at thinking, memory, and mood changes in adults in France taking ALK/ROS1-targeted drugs for metastatic lung cancer to see how these effects affect daily life and to build a patient-research care pathway.

  Recruiting at 2 sites Hospices Civils de Lyon · Bron and 1 other locations · NCT06781905

• Evaluating BBO-10203 for advanced solid tumors

  This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.

  Recruiting at 43 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Duarte, California and 43 other locations · NCT06625775

• Pulsed radiotherapy with immunotherapy for metastatic non-small cell lung cancer that stopped responding to prior treatment

  This phase 1 study tests whether giving adaptive pulsed radiotherapy together with PD-(L)1 inhibitors is safe and can help people with metastatic NSCLC whose cancer has progressed on immunotherapy.

  Recruiting Phase 1 Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec · NCT06622174

• Ongoing collection of blood and tumor samples from people with lung cancer

  Collect and store blood and tumor samples over time from adults with newly diagnosed or metastatic lung cancer to build a real-world biobank for research.

  Recruiting Nantes University Hospital · Angers and 3 other locations · NCT06481813

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.